Study on improving hematopoietic function of rats with blood deficiency syndrome by Shengxuebao mixture.

Background: Shengxuebao mixture (SXBM) is a novel herbal drug approved by China State Food and Drug Administration for the treatment of Leukopenia and iron deficiency anemia caused by radiotherapy and chemotherapy. Methods: To explore the mechanism of SXBM in treating blood deficiency syndrome (BDS). Firstly, network pharmacology and in vivo experiments were used to screen candidate targets and important signaling pathways of SXBM, GO functional enrichment and KEGG pathway analysis were performed. Secondly, a BDS rat model was established to verify the results of the analysis of network pharmacological enrichment. Histopathology and routine peripheral blood examination were observed. The expressions of tumor necrosis factor-α, interleukin (IL)-6, HIF-1α and NF-κB were detected by Western blot, and the expressions of IL-6, IL-1β were detected by ELISA. Results: 62 bioactive components, 66 potential targets and 131 signaling pathways of BDS were successfully identified by network pharmacology. Molecular docking simulation techniques showed that key targets tumor necrosis factor-α, IL-6, IL-1β can dock well with crucial components, and the BDS-related signaling pathways HIF-1 and JAK-STAT play a vital role. The combined model experiment of acetylphenylhydrazine and cyclophosphamide showed that the model group had obvious blood deficiency, and the histopathology and blood routine were effectively restored after administration. Our findings indicate that SXBM's therapeutic effect on BDS primarily involves the mediation of the HIF-1α/NF-κB signaling pathway and the regulation of hematopoietic factor expression. Conclusion: This study not only affirmed the protective properties of SXBM against BDS but also provided insights into a potential mechanism for blood replenishment in the treatment of BDS using SXBM. [ABSTRACT FROM AUTHOR]